Award

Effects of SGLT-2 inhibitor dapagliflozin on hormonal glucose regulation and ketogenesis in patients with type 1 diabetes

Description: SGLT-2 inhibitors currently represent the most intensely investigated drugs in the field of diabetes. SGLT-2 inhibition limits glucose reabsorption in renal tubular cells, hereby increasing the amount of glucose excreted via urine in the hyperglycemic state. Its mechanisms of action are independent of insulin, the indispensable standard of care in Type 1 Diabetes Mellitus (T1DM). Several international diabetes experts highlighted the need for adjunct therapies in T1DM. Subcutaneous application of insulin is non-physiological and interferes with many of its pharmacodynamic and pharmacokinetic properties. Most significant, subcutaneous insulin substitution does not address the bi-hormonal character of T1DM. The loss of pancreatic beta cells and subsequent endogenous insulin production uncouples alpha cell derived glucagon secretion from its paracrine suppressor. Consequently, excess glucagon concentrations occur in the fasting and the postprandial state, which promotes hyperglycemia, requires higher doses of subcutaneous insulin, and promotes glycaemic variability. Recent studies on SGLT-2 inhibition in T1DM showed better glycemic control compared to placebo, whereas a higher risk for the development of diabetic ketoacidosis was observed. Knowledge about the underlying mechanisms is scarce. Our and other working groups showed that SGLT-inhibition increased Glucagon-like-peptide 1 (GLP-1) in T1DM, an incretin hormone capable of suppressing glucagon. On the other side, total concentrations of ketone bodies were higher following SGLT-2 inhibition, irrespective of ongoing subcutaneous or intravenous insulin substitution. The present studies aim to investigate the interrelation between the SGLT-2 inhibitor dapagliflozin added to insulin and hormonal regulators of glucose homeostasis as well as to determine its net effect on glycemic control and ketogenesis in patients with T1DM. In detail, we aim to measure GLP-1, total ketone body concentrations, free fatty acids, glucagon, and somatostatin following dapagliflozin as well as to evaluate their contribution to glucose homeostasis and ketone body production during enteral and parenteral glucose administration. In addition, we aim to measure the same hormonal regulators as well as ketone bodies during and after exercise. We plan to recruit male and female patients with T1DM in two randomized, open label, cross-over intervention studies. In study 1, we will use hyperinsulinemic, euglycaemic clamps and oral glucose tolerance test clamps to determine concentrations of GLP-1, glucagon, somatostatin, and ketone bodies under intravenous insulin with concurrent enteral or parenteral glucose administration. In study 2, participants perform a recreational exercise session. We will determine the concentrations of GLP-1, glucagon, somatostatin, and ketone bodies during exercise, and evaluate glycemic control for 72 hours after exercise using continuous glucose monitoring sensors. Based on the results of our recent pilot study and other studies, we expect to find increased concentrations of GLP-1 following dapagliflozin, amplified ketone body production, and we will illustrate differences in the secretion of glucagon and somatostatin as compared to placebo. The implementation of SGLT-2-inhibition in the treatment of T1DM can be expected within the next years, yet data on hormonal regulation of glucose homeostasis and related safety are not available, particularly during exercise, which is a recommended cornerstone in the treatment of T1DM. The results of the proposed study will provide knowledge about the mechanisms underlying glycemic benefits and objectify ketone body production following SGLT-2 inhibitors in the sedentary state and during physical exercise.
Amount: CHF 265,400
Funding type: research
Funder scheme: Project funding
Start date: 2019-10-01
End date: 2023-07-31
Investigator: Laimer, Markus (lead)
Institutions: University of Bern, University of Berne – BE
Field: Medicine
Funded outputs count: 1
Funder award ID: 185019
OpenAlex ID: G681791838